drugset / Trial / NCT02541669

A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants

NCT02541669

Phase 1 Completed 64 enrolled Takeda
RandomizedParallel-groupQuadruple-blindOther

Summary

The purpose of this study is to assess the pharmacokinetics and safety of single- and multiple-dose of TAK-491 in healthy Chinese participants.

Timeline

Start
2015-11-20
Primary completion
2017-03-17
Completion
2017-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 40 mg
Subject Azilsartan medoxomil Other / unclassified 80 mg

Indications

No indication recorded.